Single high-dose intravenous immunoglobulin therapy for Kawasaki disease increases plasma viscosity

Circulation Journal

Volumn 69, Issue 8, 2005, Pages 962-964

  Baba, Reizo ^a   Shibata, Atsuko ^a   Tsurusawa, Masahito ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Globulin; Kawasaki disease; Viscosity

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN;

ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HEMATOCRIT; HUMAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PLASMA VISCOSITY; PROTEIN BLOOD LEVEL; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS;

BLOOD VISCOSITY; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RISK FACTORS; THROMBOEMBOLISM;

EID: 23744489857     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.962     Document Type: Article

References (21)

1. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-2771.
2. Imamura H, Izawa A, Kai R, Yokoseki O, Uchikawa S, Yazaki Y, et al. Trends over the last 20 years in the clinical background of young Japanese patients with coronary artery disease. Circ J 2004; 68: 186-191.
3. Onouchi Z, Hamaoka K, Sakata K, Ozawa S, Shiraishi I, Itoi T, et al. Long-term changes in coronary artery aneurysms in patients with Kawasaki disease. Circ J 2005; 69: 265-272.
4. Saji T, Sonobe T, Uemura S, Akagi T, Ayusawa M. Guideline for treatment of acute-phase Kawasaki disease. Acta Paeditrica Cardiologica Japonica 2004; 20: 54-62 (in Japanese).
5. Fruchter O, Blich M, Jacob G. Fatal acute myocardial infarction during severe thrombocytopenia in a patient with idiopathic thrombocytopenic purpura. Am J Med Sci 2002; 323: 279-280.
6. Fisman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997; 13: 775-777.
7. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 1994; 44: 223-226.
8. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy 2002; 22: 1638-1641.
9. Okuda D, Flaster M, Frey J, Sivakumar K. Arterial thrombosis induced by IVIg and its treatment with tPA. Neurology 2003; 60: 1825-1826.
10. Byrne NP, Henry JC, Herrmann DN, Abdelhalim AN, Shrier DA, Francis CW, et al. Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy. Neurology 2002; 59: 458-461.
11. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003; 60: 1822-1824.
12. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000; 75: 83-85.
13. Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIg treatment: A case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003; 56: 308-309.
14. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997; 124: 416-418.
15. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: A case report and discussion of the relevant literature. Ann Hematol 2004; 83: 661-665.
16. Rheinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992; 339: 662-664.
17. Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S. Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: Study of whole-blood viscosity. Pediatr Int 2003; 45: 156-158.
18. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991; 33: 805-810.
19. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-1639.
20. Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, et al. Selective high dose gamma-globulin treatment in Kawasaki disease: Assessment of clinical aspects and cost effeciveness. Pediatrics International 1999; 41: 1-7.
21. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-1061.